NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Peregrine Pharmaceuticals' shares might be trading below the dollar mark, but the upward trend has been promising. The company's shares rose today, to trade at $0.71 representing an impressive 4.33% rise. The industry overall has been performing well since Trump's election, but alternating sentiments with regard to regulations act to increase volatility in performance on the stock market.

In a recent dramatic turn of events regarding the GOP Healthcare bill, there are still plenty of legislative battles the Department of Health and Human Services has to overcome. During the anticipation of the results of the vote on the bill from the House of Representatives, the biotech industry's markets performance has been shaky, to say the least. The industry's volatility has been attributed to the Trump's administration ability to alter sentiments in an instant. Boitech's ETFs came crumbling down recently after the President deemed drug prices as "astronomical". Industry experts predict that a continued criticism of the industry's pricing mechanisms would contribute to the sector's diminishing profitability.

Access RDI's Peregrine Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=PPHM

Novavax Inc. closed the day on a low. With the company's share price taking a 0.79% dip by the end of business today. In a recent meeting between the industry's stakeholders and the president resulted in Trump citing reduced regulations, with regard to pricing. Novavax's share price is not as volatile as other companies', with their share price fluctuating positively.

The President also promised to reduce drug regulations, and push for easier drug approvals. This move could act to positively impact the industry's profitability with the SPDR S&P Biotech ETF XBI trading up by 0.82%, recovering from a 0.38% dip during the previous session. Industry players are still waiting for the industry to stabilize amid President Trump's new regulations that are working to increase the industry's volatility. New regulations associated with a corporate tax reduction form the current 35% to 15% are set to affect companies who export jobs abroad.

Access RDI's Novavax Research Report at: https://ub.rdinvesting.com/news/?ticker=NVAX

Our Actionable Research on Peregrine Pharmaceuticals (NASDAQ: PPHM) and Novavax, Inc. (NASDAQ: NVAX) can be downloaded free of charge at Research Driven Investing.

RDI Initiates Coverage on:

Peregrine Pharmaceuticals https://ub.rdinvesting.com/news/?ticker=PPHM

Novavax Inc. https://ub.rdinvesting.com/news/?ticker=NVAX

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com